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A B S T R A C T
Pain is a complex biopsychosocial phenomenon of which the intensity, location and duration depends on various
underlying components. Treatment of pain is associated with considerable inter-individual variability, and as
such, requires a personalized approach. However, a priori prediction of optimal analgesic treatment for
individual patients is still challenging. Another challenge is the assessment and treatment of pain in patients
unable to self-report pain. In this mini-review, we ﬁrst provide a brief overview of the various components
underlying pain, and their associated biomarkers. These include clinical, psychosocial, neurophysiological, and
biochemical components. We then discuss the use of empirical and mechanism-based pharmacokinetic-
pharmacodynamic modelling to support personalized treatment of pain. Finally, we propose how these concepts
can be extended to a quantitative systems pharmacology (QSP) approach that integrates the components of
clinical pain and treatment response. This integrative approach can support predictions of optimal pharma-
cotherapy of pain, compared with approaches that focus on single components of pain. Moreover, combination
of QSP modelling with state-of-the-art metabolomics approaches may oﬀer unique possibilities to identify novel
pain biomarkers. Such biomarkers could support both the personalized treatment of pain and translational drug
development of novel analgesic agents. In conclusion, a QSP approach will likely improve our ability to predict
pain and treatment response, paving the way for personalized treatment of pain.
1. Introduction
Pain has been deﬁned as an “unpleasant sensory and emotional
experience associated with actual or potential tissue damage” (Merskey
and Bogduk, 1994), and involves a complex interplay of neurophysiol-
ogy (Vardeh et al., 2016), psychosocial factors (Mao, 2012), and
inﬂammatory processes (Ji et al., 2016). Pain and treatment response
for both acute and chronic pain is associated with substantial inter-
individual variability (Aubrun et al., 2012; Gilron et al., 2013; Hinrichs-
Rocker et al., 2009). For acute postoperative pain, analgesic drugs are
generally titrated based on the patient's self-reported pain levels,
because a priori prediction of eﬀective pain treatment is diﬃcult
(Aubrun et al., 2012). In many chronic pain conditions, many patients
do not achieve even moderate pain relief from the various available
drug therapies (Gilron et al., 2013). Consequently, for chronic pain
there is a need to predict both the type of drugs and their dosage
regimen that will optimally treat the individual patient. Finally, not all
patients are able to self-report pain, for instance due to unconscious-
ness, cognitive impairment or young age (< 3 years).
There is a major unmet clinical need for biomarkers and patient
characteristics that can guide personalized treatment of pain in the
individual patient. Various components underlie the large inter-indivi-
dual variability of pain and treatment response, including clinical,
psychosocial, neurophysiological and pharmacological components
(Apfelbaum et al., 2003; Borsook et al., 2011; Hinrichs-Rocker et al.,
2009). By providing a quantitative insight into the underlying compo-
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nents of pain, biomarkers for pain or treatment response could
contribute to personalized treatment in several ways: i) pain monitoring
in patients where self-report is not possible ii) diagnosis of pain
conditions iii) a priori prediction of optimal treatment (Backryd,
2015; Beger et al., 2016). Additionally, biomarkers of treatment
response can contribute to dose-ﬁnding during drug development
(Frank and Hargreaves, 2003; Taneja et al., 2016).
Characterizing the inter-individual variability in the underlying
components of pain might support the personalized treatment of pain.
For example, patient-speciﬁc predictors of pharmacokinetics have been
used to optimize morphine dose regimens in pediatric patients (Krekels
et al., 2014). However, the right drug and dose regimen for individual
patients are unlikely to be predicted on the basis of pharmacokinetics
alone (Krekels et al., 2014). Arguably, the lack of studies integrating the
aforementioned components underlying pain and treatment response is
prohibiting development of personalized medicine strategies. In our
view, pain cannot be truly understood mechanistically nor well
predicted, when components of the underlying system are studied in
isolation. Thus, an approach that integrates these components would
support the use and development of biomarkers to guide personalized
treatment of pain.
In this report, we ﬁrst provide an overview of outcome metrics and
candidate biomarkers of pain, and the pain-related (biological) pro-
cesses that they inform on (Table 1). Next, we discuss the use of
empirical and mechanism-based pharmacokinetic-pharmacodynamic
modelling of clinical pain. Finally, we propose how these concepts
can be extended to a quantitative systems pharmacology (QSP)
approach that integrates the components and biomarkers of clinical
pain to enable personalized treatment.
2. Underlying Components of Clinical Pain
2.1. Clinical Pain Assessment
Patient self-reporting is the gold standard for clinical pain assess-
ment (Herr et al., 2011; McCaﬀery, 1968). Typically, unidimensional
scales are used, such as the visual analogue scale and numerical rating
scale (Younger et al., 2009). Multidimensional pain scales have
additional items that incorporate other aspects of pain, such as impact
on quality of life and interference with daily life. Such factors are
especially relevant in chronic pain conditions, where pain intensity
ratings alone correlate poorly with the impact on quality of life (Lame
et al., 2005). Examples of multidimensional pain scales include the
West Haven-Yale Multidimensional Pain Inventory and the Treatment
Outcomes of Pain Survey (Kerns et al., 1985; Rogers et al., 2000).
Behavioural pain scales are used to assess pain in patients unable to
self-report (Herr et al., 2011). Examples of such scales include the
COMFORT behaviour scale for neonates and infants, and the REPOS
and PAINAD scales for patients with advanced dementia (van Dijk
et al., 2000; van Herk et al., 2009; Warden et al., 2003). Such scales
quantify pain-associated behaviour, such as facial tension, moaning and
crying. It is, however, diﬃcult to discriminate between behaviour from
pain and that from other sources of emotional or physiological distress
(Herr et al., 2011; Pasero and McCaﬀery, 2005). Alternative surrogate
pain markers focusing on autonomous nervous system responses
include skin conductance, heart rate variability and pupillometry
(Cowen et al., 2015). However, similar to the behaviour scales, these
markers are aﬀected by both pain and other types of distress (Baarslag
et al., 2017).
2.2. Psychosocial Contributors to Clinical Pain
Pain perception and treatment response are inﬂuenced by a number
of psychosocial factors including psychiatric comorbidities (e.g., de-
pression, anxiety, stress), social support, and patient expectations (e.g.,
nocebo and placebo eﬀects) (Colloca et al., 2013; Gil et al., 1990;
Hinrichs-Rocker et al., 2009; Ip et al., 2009; Linton and Shaw, 2011;
Masselin-Dubois et al., 2013; Sturgeon and Zautra, 2013; Wiech, 2016).
One example is pain catastrophizing, which is the tendency to feel
helpless about pain, to magnify the perceived threat level of pain and to
be unable to inhibit pain-related thoughts (Quartana et al., 2009;
Sullivan et al., 1995). Pain catastrophizing has been associated with a
decreased response to analgesic treatment and worse pain-related
outcomes (Fillingim et al., 2005; Haythornthwaite et al., 2003;
Quartana et al., 2009).
Placebo and nocebo eﬀects can respectively induce relief or
increased pain experience through expectation and previous experience
(Reicherts et al., 2016). Additionally, placebo analgesia has a strong
neurobiological component, with involvement of various endogenous
neuromodulators (Colloca et al., 2013). The eﬀect of placebo can be
quantiﬁed separately from the drug eﬀect in studies that include
placebo treatment arms (Anderson et al., 2001; Bjornsson and
Simonsson, 2011). However, when eﬀective treatment exists, treatment
with placebo alone might not be ethically possible, thus limiting the
ability to quantify the placebo eﬀect (Arnstein et al., 2011). Another
approach to study the contribution of placebo analgesia is the compar-
ison of covert and overt administration of analgesics. For example,
Amanzio et al. showed that required doses are higher if analgesics are
administered covertly, indicating the contribution of placebo eﬀects to
the clinical eﬃcacy of analgesics (Amanzio et al., 2001).
2.3. Neurophysiological Biomarkers
The neurophysiology of pain has been extensively studied with
electrophysiological and imaging techniques (Lee and Tracey, 2013;
Schweinhardt and Bushnell, 2010). Brain imaging studies have linked
activity in several regions of the brain to pain and nociception,
however, none of these areas are exclusively activated by pain nor do
any of these appear to be crucial for pain experience (Melzack, 2001).
Additionally, these techniques can be used to identify diﬀerences in the
neurophysiology of pain in special patient populations (e.g., children of
various age groups) (Sava et al., 2009).
Thus far, it has proved challenging to use neurophysiological
biomarkers to quantify pain levels in the individual patient with
suﬃcient sensitivity and speciﬁcity (Davis et al., 2012). However, on
a population level, several neurophysiological biomarkers have been
associated with pain. For example, an EEG-based template was recently
proposed as a measure for nociceptive brain activity in infants (Hartley
et al., 2017). A priori predictors from fMRI have emerged in areas of
experimental pain, postoperative pain, and chronic pain (Baliki et al.,
2012;Gram et al., 2017; Huang et al., 2013; Lee and Tracey, 2013). For
example, brain activity in regions associated with emotional appraisal
during anticipation of pain can partially predict inter-individual
variability in placebo response (Colloca et al., 2013). Additionally,
imaging might contribute to clinical diﬀerentiation of chronic pain
subtypes (Borsook and Becerra, 2011).
Imaging approaches form a potential method to characterize the
neurophysiological interactions between pain, nociception, psychology
and analgesic treatment. For example, PET and fMRI studies have
linked placebo analgesia to opioidergic pathways of descending pain
modulation in the anterior cingulate cortex, the periaqueductal grey
and the spinal dorsal horn (Lee et al., 2014). It has also been suggested
that placebo and nocebo eﬀects act on distinct areas of the brain (Bingel
et al., 2011; Lee et al., 2014). Pain catastrophizing has been associated
with altered pathways of endogenous pain inhibition, and increased
activity in regions associated with the anticipation, attentional and
emotional aspects of pain (Quartana et al., 2009). Finally, the treatment
of pain with opioids and NSAIDs has been linked to changes in the
activity of pain-related regions, and some studies have even looked at
the sensitivity of diﬀerent regions to these pharmacological eﬀects
(Hodkinson et al., 2015; Lee et al., 2014; Oertel et al., 2008).
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2.4. Molecular Proﬁling of Pain
Molecular proﬁling technologies (e.g. genomics, transcriptomics,
proteomics, metabolomics) provide quantitative insight into the biolo-
gical processes that underlie clinical pain (Chen and Snyder, 2013;
Wishart, 2016). Examples of these processes include inﬂammation,
endogenous pain modulation, and nociception (Backryd, 2015; Chizh
et al., 2008). While blood may not the primary matrix of interest for
pain and nociception, biomarker proﬁles in blood related to signalling
molecules might still capture these pain-associated biological processes
in other tissues (Chen and Snyder, 2013). A large number of studies
have implicated a role for genetics in the inter-individual variability in
both experimental and clinical pain (Mogil, 2012). However, genetic
associations have so far not been consistently replicated, nor have
robust genetic predictors of inter-individual variability been identi-
ﬁed—with the exception of some hereditary monogenic pain disorders
(Mogil, 2012).
Metabolomics aims to characterize the metabolome, i.e. the entire
spectrum of small molecule products that result from genetic, transcrip-
tional and environmental inﬂuences. Metabolomics provides the closest
biochemical representation of an individual's clinical phenotype and is
therefore a promising source of new clinical biomarkers (Beger et al.,
2016;Kohler et al., 2017 this issue). Proteomics can complement
metabolomics as a source of candidate biomarkers, by quantifying
proteins and peptides that function as signalling molecules in processes
related to pain (Backryd, 2015). Currently, no single robust biomarker
for pain perception has emerged from proteomic- or metabolomics
approaches (Backryd, 2015). So far, potential pain biomarkers have
been identiﬁed in processes such as inﬂammation (prostaglandins,
cytokines, chemokines) and endogenous pain modulation (neuropep-
tides, endocannabinoids, neurosteroids) (Backryd et al., 2014; Kilts
et al., 2010; Symons et al., 2015; Taneja et al., 2016). Additionally,
metabolomics might also inform on psychological risk factors for
increased pain, such as chronic stress and pain catastrophizing
(Hinrichs-Rocker et al., 2009; Russell et al., 2012). For example,
elevated salivary cortisol levels were predictive of pain catastrophizing
in an experimental pain study that included pain-free subjects and
subjects with chronic pain (Quartana et al., 2010). Finally, ﬁndings
from metabolomics and proteomics studies have led to the discovery of
candidate biomarkers of the underlying pathophysiology in several
chronic pain conditions. In rheumatoid arthritis, biomarkers that reﬂect
disease activity (e.g., auto-antibodies, collagen degradation products)
might be predictive of clinical progression (McArdle et al., 2015). As
such, they might inform which patients would beneﬁt most from
aggressive treatment. In inﬂammatory bowel disease (IBD), biomarkers
in serum and faecal matter aid clinical diagnosis (i.e., diﬀerentiating
IBD from non-inﬂammatory disorders) and have a potential for use in
disease prognosis (Iskandar and Ciorba, 2012).
3. From Empirical to Mechanism-based Pharmacokinetic-
pharmacodynamic Modelling of Pain
Pharmacokinetic-pharmacodynamic (PK-PD) modelling aims to
quantitatively characterize the dynamic exposure-response relation-
ships of drugs. Here, the response can reﬂect any marker associated
with drug eﬃcacy or toxicity (Breimer and Danhof, 1997). PK-PD
modelling has become an increasingly important tool in both drug
development and personalized medicine (Mould and Upton, 2012).
Typically, PK-PD models are used in association with a nonlinear mixed
eﬀect modelling framework, which allows quantiﬁcation of inter-
individual variability. Predictors for such variability (including meta-
bolomic biomarkers) can be quantitatively incorporated in these
models.
Population PK modelling is a widely accepted approach to derive
personalized dosing regimens of analgesics by identifying patient-
speciﬁc predictors for inter-individual variability in PK (e.g. age, body
weight or organ function) (Komatsu et al., 2012; Krekels et al., 2014).
PK-PD models for clinical pain typically characterize the empirical
relationships between drug exposure and clinical pain scores (Anderson
et al., 2001; Juul et al., 2016; Mazoit et al., 2007). These empirical PK-
PD models contribute to quantitative understanding of analgesic
exposure-response relationships, by estimating parameters like the
maximum analgesic eﬀect, the concentration of half-maximum eﬀect
and the eﬀect-site equilibration rate constant (Martini et al., 2011).
These models may also include predictors of the inter-individual
variability of these parameters, which might be relevant for persona-
lized treatment. For example, Byon et al. used PK-PD modelling in
patients with ﬁbromyalgia to quantify the eﬀect of sex and age on the
maximum analgesic eﬀect of pregabalin (Byon et al., 2010).
Most PK-PD models lack a mechanistic basis or causal relationships
between the diﬀerent factors contributing to pain perception. Such
empirical PK-PD models have therefore limited use for translational
purposes, i.e. to make predictions between species or patient popula-
tions (Danhof et al., 2007). In some PK-PD studies however, biomarkers
are used as a mechanistic link between drug exposure and clinical
response. For example, Danhof and colleagues incorporated pro-in-
ﬂammatory mediators as biomarkers for the pharmacological eﬀect of
COX-2 inhibitors and linked these to clinical responses in chronic
inﬂammatory pain conditions (Huntjens et al., 2005; Taneja et al.,
2016). Quantitative EEG has been used as a biomarker for mu-opioid
receptor activity in both preclinical and clinical PK-PD modelling of
opioids (Danhof et al., 2007). Because such mechanism-based PK-PD
models characterize processes on the causal path between drug admin-
istration and eﬀect, they have important advantages in terms of
translation and prediction (Danhof et al., 2005).
4. Towards a Quantitative Systems Pharmacology Approach to
Clinical Pain
Previous sections outlined the diﬀerent components that underlie
clinical pain and the diverse range of biomarkers and predictors
associated with these components. However, the accurate prediction
of optimal pharmacotherapy in individual patients remains a challenge.
Arguably, this may be due to studies that focus on speciﬁc components
and association biomarkers in isolation. Secondly, little is known about
how the diﬀerent system components and their biomarkers interact. For
example, should we treat patients with psychological risk factors of
postoperative pain with higher analgesic doses?
Clinical pain is a problem with various interacting components, that
requires characterization at a systems level (Fig. 1) (Mao, 2012). This
calls for the use of quantitative systems pharmacology (QSP), a rapidly
emerging discipline that combines concepts from both systems biology
and PK-PD modelling (Vicini and van der Graaf, 2013). QSP approaches
enable the comprehensive characterization of pain and its underlying
pharmacological, physiological and psychological processes. Because
biomarkers can give us insight into these processes, they play a key role
in characterizing the variability and interactions of the system compo-
nents of pain and treatment response (Danhof, 2016). With an
integrative understanding of the variability in the system of pain, we
can arguably improve our ability to deliver personalized treatment,
compared to approaches that focus on a single component of the pain
(e.g., only pharmacokinetics or only psychology).
Molecular and imaging-based biomarkers can inform mechanistic
details related to QSP models of pain, because they inform us about
underlying physiological processes (Danhof et al., 2005). This could
contribute to more mechanistic characterization of drug exposure-
response relationships, and potentially be used to predict or monitor
inter-individual variability in treatment response. QSP models might
also facilitate development of novel biomarkers by providing a frame-
work for their quantitative interpretation. The quantitative under-
standing of biomarkers and their relation to pain and treatment
response is crucial if they are to be incorporated in personalized
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treatment approaches.
By moving from empiricism to mechanism, QSP approaches have
improved properties for translation and prediction (Vicini and van der
Graaf, 2013). These improved translational properties can enable the
simultaneous analysis of multiple clinical studies in comparable pain
conditions. Fig. 2 illustrates the concept of integrated analysis of data
from diﬀerent patient populations to develop a translational QSP
model. Being able to translate ﬁndings and biomarkers across diﬀerent
patient populations, would be especially beneﬁcial in patient popula-
tions that are unable of self-reporting pain. This translation will by no
means be a trivial task, as there are diﬀerences in many of the
underlying components of pain and treatment response in these
populations. For example, the neurophysiological component of pain
diﬀers between neonates and adults (Fitzgerald, 2015). The success of
these translational eﬀorts will likely depend on our ability to take these
diﬀerences into account. Moreover, it will be diﬃcult to validate
model-based personalized medicine approaches in populations without
self-report, because behavioural pain scales do not provide a direct
measure of pain perception (Herr et al., 2011). However, we would
argue that mechanism-based models and biomarkers have a greater
potential for personalized treatment in these populations than more
empirical counterparts.
The proposed QSP approach will be of relevance to drug develop-
ment as well. These models might help to identify and validate new
drug targets, or suggest suitable combinations of existing drugs (Sorger
et al., 2011). In drug development, QSP models would provide a better
basis for the prediction of optimal dose regimens and translation (e.g.,
preclinical to clinical or between diﬀerent human populations) (Vicini
and van der Graaf, 2013). Finally, the biomarkers originating from this
QSP approach might be used to improve the translational performance
of preclinical pain models.
To develop QSP models of pain, data is required that informs on the
Fig. 1. Systems view of the complexity and connectivity of clinical pain. A systems understanding of pain relies on a mechanistic understand of its underlying processes. Data types which
can provide information on this understanding include patient-reported outcomes, psychological assessments, neuroimaging and molecular markers, of which examples are shown.
Fig. 2. Integration of data from diﬀerent populations within a translational quantitative systems pharmacology (QSP) model to support personalized treatment and drug development.
CNS, central nervous system.
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underlying processes of pain. Some of the required data might be
obtained from previously conducted studies, underlining the need for
increased collaboration and data-sharing in both industry and academia
(Ince et al., 2009; Romero et al., 2010). Recent initiative to promote
these public-private partnerships include the European Innovative
Medicines Initiative (IMI), which has issued a call for project applica-
tions aiming to improve the translatability of pharmacodynamic
biomarkers in pain pathways from healthy subjects and preclinical
models (Innovative Medicines Initiative, 2016). To allow characteriza-
tion of the interactions of the systems components, future studies would
ideally quantify multiple biomarkers and potential predictors of pain in
the same patients: pain self-report, imaging/EEG-based markers, bio-
marker proﬁles in blood, psychosocial factors, drug exposure, etc. Pain
studies in healthy volunteers can complement information from clinical
studies, as they allow the study of separate system components in a
highly controlled setting (Lee and Tracey, 2013). However, the level of
psychological distress and type of noxious stimuli will diﬀer from a
clinical setting. Finally, continued development in preclinical models
such as organ-on-a-chip might also contribute to systems models by
allowing the study of isolated processes in a controlled setting (Barrett
and Haas, 2016).
5. Summary
Clinical pain is a complex and multifactorial phenomenon that has
multiple physiological and psychosocial components. This complexity
has hindered our understanding of clinical pain, the search for
predictors of inter-individual variation in pain and treatment response,
and the identiﬁcation of novel biomarkers for pain in patients unable to
self-report pain. We propose that a QSP approach will contribute
towards a quantitative understanding of the various interacting com-
ponents that underlie the variability in pain and treatment response.
Secondly, QSP approaches can complement molecular proﬁling tech-
niques such as metabolomics, in the search and development of novel
biomarkers. Therefore, QSP approaches will likely improve our ability
to predict pain and treatment response, paving the way for personalized
treatment of pain.
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